Gout - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Gout - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gout: Overview
Gout is a common and complex inflammatory arthritis which is characterized by sudden, severe attack of pain in the joints. The disease is caused due to a condition known as hyperuricemia, where there is excess amount of uric acid (a waste material) in the body. Too much uric acid can build up urate crystals that accumulate in the joints, causing inflammation, and intense pain of gout. Presence of excess levels of uric acid in the body can be either due to breakdown of purines which are found in body as well as food that is consumed or insufficient excretion by kidneys. Individuals with diabetes, poor kidney function, metabolic syndrome, obesity are likely to develop hyperuricemia which causes gout. Also, males are more prone to develop gout primarily because women tend to have lower level of uric acid. Joints that are commonly affected include ankles, knees, and the lesser toe joints.
“Gout - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gout pipeline landscape is provided which includes the disease overview and Gout treatment guidelines. The assessment part of the report embraces, in depth Gout commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gout collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve Gout.
Gout Emerging Drugs Chapters
This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gout Emerging Drugs
SEL 212: Selecta Biosciences
Selecta Bioscience’s lead drug candidate, SEL 212, is a novel combination product consisting of pegadricase (also known as pegsiticase) co-administered with synthetic vaccine particles encapsulating rapamycin (SVP-R). The drug has demonstrated good efficacy and was well tolerated in its phase II trials and is currently being evaluated for the chronic gout in its phase III trials.
URC 102: JW Pharmaceuticals
JW Pharmaceuticals “breakthrough” drug UC-102 is currently being evaluated for the treatment of gout and has demonstrated good safety and efficacy profile in phase II trials. ULC-102 is an antigout small molecule with SLC22A12 protein inhibition mechanism of action and promotes uric acid excretion.
Further product details are provided in the report……..
Gout: Therapeutic Assessment
This segment of the report provides insights about the different Gout drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Gout
There are approx. 5+ key companies which are developing the therapies for Gout. The companies which have their Gout drug candidates in the mid to advanced stage, i.e. phase III include, Selecta Biosciences and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Gout: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.
Gout Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Gout - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gout: Overview
Gout is a common and complex inflammatory arthritis which is characterized by sudden, severe attack of pain in the joints. The disease is caused due to a condition known as hyperuricemia, where there is excess amount of uric acid (a waste material) in the body. Too much uric acid can build up urate crystals that accumulate in the joints, causing inflammation, and intense pain of gout. Presence of excess levels of uric acid in the body can be either due to breakdown of purines which are found in body as well as food that is consumed or insufficient excretion by kidneys. Individuals with diabetes, poor kidney function, metabolic syndrome, obesity are likely to develop hyperuricemia which causes gout. Also, males are more prone to develop gout primarily because women tend to have lower level of uric acid. Joints that are commonly affected include ankles, knees, and the lesser toe joints.
“Gout - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gout pipeline landscape is provided which includes the disease overview and Gout treatment guidelines. The assessment part of the report embraces, in depth Gout commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gout collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve Gout.
Gout Emerging Drugs Chapters
This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gout Emerging Drugs
SEL 212: Selecta Biosciences
Selecta Bioscience’s lead drug candidate, SEL 212, is a novel combination product consisting of pegadricase (also known as pegsiticase) co-administered with synthetic vaccine particles encapsulating rapamycin (SVP-R). The drug has demonstrated good efficacy and was well tolerated in its phase II trials and is currently being evaluated for the chronic gout in its phase III trials.
URC 102: JW Pharmaceuticals
JW Pharmaceuticals “breakthrough” drug UC-102 is currently being evaluated for the treatment of gout and has demonstrated good safety and efficacy profile in phase II trials. ULC-102 is an antigout small molecule with SLC22A12 protein inhibition mechanism of action and promotes uric acid excretion.
Further product details are provided in the report……..
Gout: Therapeutic Assessment
This segment of the report provides insights about the different Gout drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Gout
There are approx. 5+ key companies which are developing the therapies for Gout. The companies which have their Gout drug candidates in the mid to advanced stage, i.e. phase III include, Selecta Biosciences and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Gout: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.
Gout Report Insights
- Gout Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gout drugs?
- How many Gout drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gout?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gout therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gout and their status?
- What are the key designations that have been granted to the emerging drugs?
- Selecta Biosciences
- JW Pharmaceuticals
- Astrazeneca
- Revive Therapeutics
- Fuji Yakuhin Co., Ltd.
- Arthrosi Therapeutics
- SEL 212
- URC 102
- Verinurad
- AR882
- FYU-981
Introduction
Executive Summary
Gout: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gout – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gout companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gout Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SEL 212: Selecta Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
URC-102: JW Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Gout Key Companies
Gout Key Products
Gout- Unmet Needs
Gout- Market Drivers and Barriers
Gout- Future Perspectives and Conclusion
Gout Analyst Views
Gout Key Companies
Appendix
Executive Summary
Gout: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gout – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gout companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gout Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SEL 212: Selecta Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
URC-102: JW Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Gout Key Companies
Gout Key Products
Gout- Unmet Needs
Gout- Market Drivers and Barriers
Gout- Future Perspectives and Conclusion
Gout Analyst Views
Gout Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Gout
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Gout
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Gout
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Gout
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
